What is the purpose of this study?
The purpose of this study is to find a recommended dose level of LY2940680 that can be safely given to children with medulloblastoma or rhabdomyosarcoma that has returned or doesn't respond to initial treatment. The study will also explore the changes in a cancer marker levels. Finally, the study will help document any antitumor activity.
Who can participate?
Patients between the ages of 12 months to 21 years with medulloblastoma or rhabdomyosarcoma are eligible for this study. For further information on inclusion criteria, download or print the PDF for this study below.